Exciting News from Adtec Healthcare!
We’re thrilled to announce a significant milestone in our journey towards securing external investment for Adtec Healthcare Limited. After a period of productive and collaborative discussions, we’re proud to share that we have officially signed the Term Sheet with our investment and business partners.
This marks a monumental step forward, paving the way for the completion of the investment process over the next 1-2 months. Once finalised, this investment would enable us to accelerate the expansion of our business into new territories, bringing our SteriPlas Premium Cold Plasma medical device to even more markets where it can make a real difference in wound care and infection management.
We’re incredibly excited about the future and the opportunities this partnership could unlock. A huge thank you to our dedicated team, partners, and supporters who have been with us every step of the way.
Stay tuned as we move closer to the final stages of this journey — we can’t wait to share what’s next!
Exciting news for SteriPlas activity in Taiwan
Exciting Success for SteriPlas Cold Plasma in Taiwan!
We are proud to share incredible news from our trusted medical distributor, SG Biomedical, who have successfully introduced our SteriPlas Premium Cold Plasma medical device to six leading hospitals across Taiwan. Over 100 patients have been treated in 2024 with remarkable outcomes.
These patients presented with complex wound infections, including:
🩺 Diabetic foot ulcers
🩺 Pressure ulcers
🩺 Chronic burns
🩺 Skin graft donor site complications
🩺 Autoimmune disease-associated wounds
🩺 LVAD infections
🩺 Cellulitis
🩺 Post-surgical wounds
Ranging from ages 29 to 104, all patients had previously suffered from stalled healing due to chronic biofilm complications. After treatment with the SteriPlas, patients have experienced positive healing outcomes, with many achieving full recovery and others showing ongoing progress toward healing. Importantly, no side effects have been observed during treatments.
This breakthrough highlights the transformative impact of the SteriPlas on chronic infections where other treatments have failed. We're immensely grateful to SG Biomedical and the healthcare professionals who continue to deliver life-changing care to patients in Taiwan.
Together, we’re redefining possibilities in wound care.
Adtec joins the MedTech World 2024 this week
We’re thrilled to announce our participation in MedTech World 2024 this week!
Join us as our CEO takes the stage for the panel discussion, "How We Do It: Investors and Entrepreneurs Together." This is a fantastic opportunity to explore innovative collaborations that drive the future of healthcare technology.
Stay tuned for insights and highlights from the event! Let’s connect and shape the future of MedTech together!
https://med-tech.world/news/improving-wound-management-adtec-healthcares-steriplas-technology-explained/
Medica Trade Fair 2023
We are delighted to be joining The Association of British HealthTech Industries (ABHI) and UK Healthcare Pavilion at the Medica Trade Fair next week, showcasing the strengths of UK HealthTech alongside 40 of the UK’s leading industry players. Come visit us at booth J60.3, Hall 16 and discover the best of the UK.
TFDA Approves SteriPlas in Taiwan
It is with great pleasure that we announce the SteriPlas Cold Plasma medical device is now an approved product in Taiwan, making it the first Cold Plasma medical device to be issued in the country. Adtec Healthcare Limited owes its thanks and praises to our exclusive distributor in Taiwan, SG Biomedical, whom without their skills in Regulatory and with the TFDA, none of this would have been possible.
The SteriPlas is already renowned in Taiwan for its strong clinical efficacy using premium and dense Cold Plasma and is set for distribution across the leading hospitals dealing with wound care. This is set to start within the coming months. If you are a health care professional in Taiwan that manages chronic wounds, we humbly request that you contact SG Biomedical who can guide you on the strong antibacterial benefits of the SteriPlas for diabetic foot ulcers, LVAD infections, sternal wounds and many more.
http://www.sghlds.com/index.php/tw/
Adtec presents at the LSI today
It was a pleasure to present at the LSI - Life Science Intelligence in Barcelona today. The successes of Adtec Healthcare Ltd and our Premium Cold Plasma medical device, the SteriPlas, were presented to the audience with much interest.
If you would like to know more about our strong clinical efficacy and antibiofilm properties for chronic wounds and infections, send us an email at info@adtecplasma.com
First day at the LSI
An epic start to the first day at LSI - Life Science Intelligence in Barcelona.
It has been a pleasure to interact with professionals sharing the same interest in tackling strains on the global wound care market. The benefits that the clinically proven SteriPlas can bring to significantly reduce bed occupancy, chronic infections and the financial burden rates have been demonstrated.
We look forward to presenting more about this on the 21st Sept and encourage you to meet with us whilst at LSI to learn more about our Premium Cold Plasma medical device for chronic wounds, surgical site infections and medical dermatology conditions.
Life Science Intelligence Conference in Barcelona
Adtec Healthcare Ltd will be presenting at the Life Science Intelligence (LSI) Barcelona from 18-22 September 2023. Our Managing Director, Mary, will be showcasing the successes Adtec Healthcare and the SteriPlas have brought to clinical practices dealing with non-healing chronic wounds burdened with biofilm. Mary’s presentation will be held at 10:35 - 10:44 on September 21st and we encourage you to attend and ask your questions to better learn why we remain the leader of high density Cold Plasma medicine.
Advanced Wound Care Summit 2023
We’re looking forward to presenting at the Advanced Wound Care Summit in Boston, USA in 2 weeks. Our Managing Director, Mary McGovern, will be presenting on our SteriPlas Cold Plasma and the strong benefits it brings to preventing amputations, reducing bed occupancy and saving lives.
Our presentation, “Cold Argon Plasma: A Powerful Tool for Infection Management, Biofilm Destruction and AMR” will explain our clinical evidence on the infection management of chronic, non-healing and infected wounds, impact of argon plasma on biofilm and the use of cold argon plasma in the fight against antimicrobial resistance.
We’re also open to meetings during the conference and would welcome your interest in our proven and patented technology. Send us an email at info@adtecplasma.com to learn more.
Adtec Healthcare Limited celebrates today
We’re excited today to celebrate the establishment of Adtec Healthcare Limited as a separate entity from Adtec Europe Ltd. Adtec Healthcare Limited, originally part of the European subsidiary of its parent company Adtec Plasma Technology Japan, was the first company worldwide to introduce Cold Plasma on wounds in clinical trials. Adtec Healthcare offers its thanks and praises to Adtec Plasma Technology Japan for its continued financial support and guidance which without whom we would not be the leading Cold Plasma company we are today.
What does this mean for us?
Now officially exclusively operating as a Healthcare company, we can speak with investors and wound care companies to introduce our patented technology and collaborate to accelerate sales in Europe as well as launching the technology in the USA where a strong interest for Adtec Healthcare’s Cold Plasma from clinicians has already been established. The new investment will be used towards clinical studies and gaining FDA approval.
What does this mean for you?
Adtec Healthcare Limited will continue to operate from its office in London and our working relationships with distributors and customers will continue as normal. Our company’s footprint is set to expand, and we will be in touch in the coming months to update you of our progress.
The experienced Adtec Healthcare Limited team, led by Mary McGovern, are excited to start this next chapter on their mission to revolutionize the global wound care market working alongside financial and strategic partners.